Success Metrics

Clinical Success Rate
33.3%

Based on 2 completed trials

Completion Rate
33%(2/6)
Active Trials
1(14%)
Results Posted
250%(5 trials)
Terminated
4(57%)

Phase Distribution

Ph not_applicable
1
14%
Ph phase_1
1
14%
Ph phase_2
5
71%

Phase Distribution

1

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(2)
Terminated(4)

Detailed Status

Terminated4
Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (14.3%)
Phase 25 (71.4%)
N/A1 (14.3%)

Trials by Status

active_not_recruiting114%
terminated457%
completed229%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_2

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849
completedphase_2

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

NCT01982682
completedphase_2

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

NCT00571662
terminatedphase_2

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

NCT00914940
terminatedphase_1

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02057770
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01746849Phase 2

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Active Not Recruiting
NCT01982682Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

Completed
NCT00571662Phase 2

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Completed
NCT00914940Phase 2

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Terminated
NCT02057770Phase 1

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated
NCT01598025Not Applicable

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Terminated
NCT00589602Phase 2

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

Terminated

All 7 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
7